RedHill Biopharma announces U.S. commercialization agreement for FDA-approved GI product
RedHill Biopharma announced it has entered into a commercialization agreement with ParaPRO, an Indiana-based specialty pharmaceutical company, granting RedHill the exclusive rights to promote Esomeprazole Strontium Delayed-Release Capsules to gastroenterologists in certain U.S. territories. August 17, 2017